<DOC>
	<DOCNO>NCT00033293</DOCNO>
	<brief_summary>This randomized phase III trial study cyclophosphamide , prednisone , immunoglobulin see well work compare cyclophosphamide prednisone alone treat patient abnormal eye trunk muscle movement ( know opsoclonus myoclonus ataxia ) associate neuroblastoma . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Steroid therapy decrease inflammation . Combining chemotherapy steroid therapy immunoglobulin may effective treat abnormal muscle movement associate neuroblastoma . Chemotherapy ( cyclophosphamide ) , prednisone intravenous gamma globulin suppress immune system may helpful treat opsoclonus-myoclonus-ataxia ( OMA ) .</brief_summary>
	<brief_title>Cyclophosphamide Prednisone With Without Immunoglobulin Treating Abnormal Muscle Movement Children With Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine immunosuppressive therapy cyclophosphamide prednisone effective therapy neuroblastoma associate opsoclonus-myoclonus-ataxia ( OMA ) constitute back-bone therapy upon build additional therapy . II . Determine randomize study addition intravenous gammaglobulin therapy back-bone therapy prednisone cyclophosphamide improve response neuroblastoma associate OMA . SECONDARY OBJECTIVES : I . Determine intravenous gammaglobulin therapy improve motor coordination child diagnose neuroblastoma present OMA syndrome assess neurological examination Vineland Adaptive Behavior Scale ( VABS ) . II . Determine regimens improve functional outcome patient . III . Investigate biology neuroblastoma associate OMA , specific regard magnetic resonance imaging ( MRI ) finding , anti-neuronal antibody , cerebrospinal fluid ( CSF ) finding tumor biology . IV . Define good long-term prognosis neurologic recovery child neuroblastoma associate OMA syndrome . V. Define event-free overall survival patient neuroblastoma associate opsoclonus-myoclonus-ataxia syndrome . OUTLINE : CHEMOTHERAPY : Patients intermediate-risk high-risk neuroblastoma receive chemotherapy ( include cyclophosphamide ) accord standard care stage primary neuroblastoma , begin day 0 . Patients low-risk neuroblastoma ( receive chemotherapy ) receive cyclophosphamide IV 1 hour day 0 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . All patient receive oral prednisone twice daily 3 month every day 7-15 month . IMMUNE GLOBULIN THERAPY : Patients randomize 1 2 treatment arm . ARM I : Patients receive immune globulin IV day -2 -1 , week 4 , 8 , 12 , 16 , 20 , 24 , month 8 , 10 , 12 therapy . Treatment continue absence disease progression unacceptable toxicity . Patients response 6 month go treatment . ARM II : Patients receive immune globulin . Patients unresponsive opsoclonus-myoclonus-ataxia syndrome 2 month progression 6 month may cross arm I . Patients follow therapy every month 6 month , 1 year , annually 10 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Corticotropin-Releasing Hormone</mesh_term>
	<mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>beta-Endorphin</mesh_term>
	<criteria>Newly diagnose neuroblastoma ( NBL ) ganglioneuroblastoma tumorassociated opsoclonusmyoclonusataxia syndrome ( OMA ) Patients NBL diagnose within 6 month OMA diagnosis AND patient OMA diagnose within 6 month NBL diagnosis eligible Must enroll study within 4 week diagnosis Presence opsoclonus , myoclonus , and/or ataxia associate neuroblastoma consider eligible Currently enrol COG neuroblastoma protocol : COGANBL00B1 successor No prior IV gamma globulin therapy No prior chemotherapy Concurrent chemotherapy allow No prior prednisone corticotropin Patients receive â‰¤ 14 day steroid eligible Concurrent surgery allow Patients must free organ dysfunction disorder treat physician feel may preclude use corticosteroid therapy ( ACTH prednisone ) , cyclophosphamide therapy intravenous gammaglobulin therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>